189 related articles for article (PubMed ID: 29405437)
21. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
22. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
Ross C; Marshman G; Grillo M; Stanford T
Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
[TBL] [Abstract][Full Text] [Related]
23. Effects of tumor necrosis factor α inhibitors extend beyond psoriasis: insulin sensitivity in psoriasis patients with type 2 diabetes mellitus.
Al-Mutairi N; Shabaan D
Cutis; 2016 Mar; 97(3):235-41. PubMed ID: 27023086
[TBL] [Abstract][Full Text] [Related]
24. Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
Heinecke GM; Luber AJ; Levitt JO; Lebwohl MG
J Drugs Dermatol; 2013 Oct; 12(10):1098-102. PubMed ID: 24085044
[TBL] [Abstract][Full Text] [Related]
25. Small low-density lipoprotein and small low-density lipoprotein/total low-density lipoprotein are closely associated with intima-media thickness of the carotid artery in Type 2 diabetic patients.
Inukai T; Yamamoto R; Suetsugu M; Matsumoto S; Wakabayashi S; Inukai Y; Matsutomo R; Takebayashi K; Aso Y
J Diabetes Complications; 2005; 19(5):269-75. PubMed ID: 16112502
[TBL] [Abstract][Full Text] [Related]
26. Long persistence of tumour necrosis factor-α antagonist-induced autoantibodies under subsequent treatment with ustekinumab but no adverse effects: a case study of 14 patients with psoriasis.
Hoffmann JHO; Knoop C; Enk AH; Hadaschik EN
Br J Dermatol; 2018 Jan; 178(1):e9-e10. PubMed ID: 28581119
[No Abstract] [Full Text] [Related]
27. Reduced risk of mortality associated with systemic psoriasis treatment in the Psoriasis Longitudinal Assessment and Registry (PSOLAR): A nested case-control analysis.
Langley RG; Poulin Y; Srivastava B; Lafferty KP; Fakharzadeh S; Langholff W; Augustin M
J Am Acad Dermatol; 2021 Jan; 84(1):60-69. PubMed ID: 32798580
[TBL] [Abstract][Full Text] [Related]
28. Medication adherence among patients with psoriasis on traditional systemic and biologics treatment.
Hambly R; Kelly A; Gilhooley E; Nic Dhonncha E; Murad A; Hughes R; Lally A; Kirby B
Br J Dermatol; 2018 Jan; 178(1):e46-e48. PubMed ID: 28762482
[No Abstract] [Full Text] [Related]
29. Carotid intima-media thickness in psoriatic arthritis: differences between tumor necrosis factor-α blockers and traditional disease-modifying antirheumatic drugs.
Di Minno MN; Iervolino S; Peluso R; Scarpa R; Di Minno G;
Arterioscler Thromb Vasc Biol; 2011 Mar; 31(3):705-12. PubMed ID: 21212403
[TBL] [Abstract][Full Text] [Related]
30. Subclinical atherosclerosis in patients with chronic psoriasis: a potential association.
El-Mongy S; Fathy H; Abdelaziz A; Omran E; George S; Neseem N; El-Nour N
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):661-6. PubMed ID: 19888942
[TBL] [Abstract][Full Text] [Related]
31. Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.
Savage L; Goodfield M; Horton L; Watad A; Hensor E; Emery P; Wakefield R; Wittmann M; McGonagle D
Arthritis Rheumatol; 2019 Apr; 71(4):626-631. PubMed ID: 30468001
[TBL] [Abstract][Full Text] [Related]
32. Long-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertension.
Napoli C; Bruzzese G; Ignarro LJ; Crimi E; de Nigris F; Williams-Ignarro S; Libardi S; Sommese L; Fiorito C; Mancini FP; Cacciatore F; Liguori A
Am Heart J; 2008 Dec; 156(6):1154.e1-8. PubMed ID: 19033012
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting.
Küster D; Nast A; Gerdes S; Weberschock T; Wozel G; Gutknecht M; Schmitt J
Arch Dermatol Res; 2016 May; 308(4):249-61. PubMed ID: 26961372
[TBL] [Abstract][Full Text] [Related]
34. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
[TBL] [Abstract][Full Text] [Related]
35. The effects of simvastatin and levothyroxine on intima-media thickness of the carotid artery in female normolipemic patients with subclinical hypothyroidism: a prospective, randomized-controlled study.
Duman D; Demirtunc R; Sahin S; Esertas K
J Cardiovasc Med (Hagerstown); 2007 Dec; 8(12):1007-11. PubMed ID: 18163011
[TBL] [Abstract][Full Text] [Related]
36. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
[TBL] [Abstract][Full Text] [Related]
37. Carotid intima-media thickness and serum leptin in psoriasis.
Enany B; El Zohiery AK; Elhilaly R; Badr T
Herz; 2012 Aug; 37(5):527-33. PubMed ID: 22127739
[TBL] [Abstract][Full Text] [Related]
38. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
[TBL] [Abstract][Full Text] [Related]
39. Association between clinical factors and dose modification strategies in the treatment with ustekinumab for moderate-to-severe plaque psoriasis.
Romero-Jimenez RM; Escudero-Vilaplana V; Baniandres Rodriguez O; García Martín E; Mateos Mayo A; Sanjurjo Saez M
J Dermatolog Treat; 2018 Dec; 29(8):792-796. PubMed ID: 29676189
[TBL] [Abstract][Full Text] [Related]
40. Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis.
Raposo I; Bettencourt A; Leite L; Selores M; Torres T
Acta Med Port; 2019 Mar; 32(3):214-218. PubMed ID: 30946793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
